Share This Page

Alz Week 3

Your Name Here

Weekly Newsletter

Connecting Alzheimer's & Dementia Organizations to Supporters & Clients

Sign up

Leqembi Launched in China to Fight Alzheimer’s

China is the third country to launch LEQEMBI for sale, to fight Alzheimer's, following the United States and Japan.
Leqembi (Lecanemab)

The launch of LEQEMBI in China marks an important milestone in the fight against Alzheimer’s disease. 

With a high prevalence of the disease in the country, this innovative treatment option brings hope to millions of patients and their families who have been desperately seeking effective therapies1.

LEQEMBI, also known as Lecanemab, is a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody. It selectively binds to both soluble Aβ aggregates (protofibrils) and insoluble Aβ aggregates (fibrils), reducing Aβ plaques in the brain. 

Notably, LEQEMBI is the world’s first approved treatment shown to slow cognitive and functional decline in Alzheimer’s patients through this mechanism2.

Its launch in China provides a crucial opportunity for early detection, diagnosis, and treatment, supporting those affected to “live their fullest lives.

Foot Notes:

  1. LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China: China Becomes the Third Country to Launch LEQEMBI Following the United States and Japan
  2. “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

Related:

Email me when people comment
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Free Weekly Newsletter. Sign up here.
Alzheimer's & Dementia Weekly

You May LIke:
Diet

Fish, Omega-3, Dementia

Dr. Michael Gregger, Director of the authoritative NutritionFacts site, asks, “Why has fish consumption been associated with cognitive impairment and loss of executive function?”

Read More »
No Comments
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

Facebook-f Youtube
0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter